# PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PRCT
## Company Profile
- Ticker: PRCT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 20.03 USD
- Market cap: 1523148265.44 USD
- Last updated: 2026-08-06
## Business Overview
### Urology Robotics
PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies.
### Aquablation Therapy
Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive prostate tissue. The procedure is planned from imaging and is intended to reduce dependence on surgeon technique compared with manually executed resection.
### HYDROS Platform
The HYDROS Robotic System is the company’s current AI-enabled platform for Aquablation. Its FirstAssist AI software supports personalized image-guided planning, while recurring handpiece sales create a procedure-linked revenue stream alongside capital-system placements.
## Why The Stock Is Moving

As of Aug 6, 2026, PRCT closed up 3.57% at $20.03. No new same-company headline was identified in the current news window.

## Future Catalysts

- PROCEPT BioRobotics's catalysts are Aquablation adoption, prostate-procedure growth, and continued system rollout. The company matters most when the procedure base keeps widening.

## Recent News
- 2026-08-04 20:05 EST — [PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-second-quarter-2026-financial-results-325eefde) — Source: PROCEPT BioRobotics
- 2026-07-14 20:05 EST — [PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd) — Source: PROCEPT BioRobotics
- 2026-05-28 12:00 EST — [PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval](https://biopharmsignal.com/news/PRCT/procept-biorobotics-advances-prostate-cancer-program-with-water-iv-study-enrollm-de942ff2) — Source: PROCEPT BioRobotics
- 2026-05-14 12:00 EST — [AUA Guidelines Strengthen Recommendation for Aquablation® Therapy](https://biopharmsignal.com/news/PRCT/aua-guidelines-strengthen-recommendation-for-aquablation-therapy-b17aee34) — Source: PROCEPT BioRobotics
- 2026-04-30 20:03 EST — [PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-336852ab) — Source: PROCEPT BioRobotics